February 8, 2017 / 12:41 PM / 10 months ago

BRIEF-Can-Fite to commence patient enrollment in late-stage trial of rheumatoid arthritis drug

Feb 8 (Reuters) - Can-Fite Biopharma Ltd-

* Can-Fite gears up for acrobat, its phase III trial of piclidenoson in rheumatoid arthritis

* To commence patient enrollment in Q2 2017 in phase III trial of lead drug candidate piclidenoson for rheumatoid arthritis treatment

* Piclidenoson phase III trial, titled acrobat, will enroll approximately 500 patients in europe, canada and israel Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below